BeyondSpring Inc. (BYSI)
1.75
-0.01 (-0.85%)
At close: Jan 22, 2025, 3:55 PM
1.75
0.00%
After-hours Jan 22, 2025, 03:56 PM EST
undefined% (undefined)
| Bid | 1.73 |
| Market Cap | 70.53M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.4 |
| PE Ratio (ttm) | -4.37 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.76 |
| Volume | 40,267 |
| Avg. Volume (20D) | 25,176 |
| Open | 1.76 |
| Previous Close | 1.76 |
| Day's Range | 1.66 - 1.76 |
| 52-Week Range | 0.87 - 4.00 |
| Beta | undefined |
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combinati...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 2017
Employees 36
Stock Exchange NASDAQ
Ticker Symbol BYSI
Analyst Forecast
According to 1 analyst ratings, the average rating for BYSI stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
